(Philadelphia, PA) - In the May 3 issue of the Journal of the American Medical Association, Brian L. Strom, MD, MPH, Professor of Public Health and Preventive Medicine and Chair of the Department of Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine, analyzes the limitations of the current system of drug-safety monitoring and proposes a solution that addresses overly aggressive early marketing practices; an absence of incentives to complete post-marketing safety studies; direct-to-consumer (DTC) advertising that can promote non-critical use of "blockbuster" drugs; the current trend toward delaying drug approval; and public misunderstanding about the safety of drugs. As Strom writes, "the net effect of [the current system] is that the public misunderstands drug safety, believing that a drug is safe at the time of marketing, while [adverse] events occurring as frequently as 1 in 1000 are predictably undetected."

Strom proposes an alternative approach with three elements: conditional approval, an empowered US Food and Drug Administration (FDA), and a complementary nongovernmental organization.

When a drug is initially approved, it should ideally enter a period of conditional approval, he says. In this period, marketing, especially DTC, would be restricted. Drug labels would need to be clearly marked that the drug's approval is conditional and has only been studied in a limited number of patients. Removal of label caveats would depend on the outcome of subsequent studies and their findings, depending on the numbers of individuals in the studies, and the risk and novelty of the drug, as well as addressing all premarketing safety questions.

"The current system is moving toward a delay in drug approval, still followed by optional postmarketing studies," notes Strom. "Instead, the proposed approach would be conditional approval followed by postmarketing studies required before the condition is removed."

Secon
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
2-May-2006

Page: 1 2
Related medicine news :

1. National quality agenda, payment reform, care integration keys to improving quality, patient safety
2. LSUHSC awarded designation resulting in improved patient safety and outcomes
3. New survey uncovers how insomnia affects job performance and safety
4. Extended duration work shifts risky to the safety, well-being of medical interns, patients
5. Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder
6. UW study to clarify safety, effectiveness of hormone therapy during menopause
7. Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW
8. U of M faculty honored by US FDA for contributions to national food safety and defense
9. Hospital errors rise 3 percent -- HealthGrades patient-safety study
10. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
11. Studies highlight real world use, safety of drug-eluting stents